New aspheric IOL designed to avoid inducing aberrations
January 1st 2006Lisbon, Portugal—A comparison study of the new aspheric SofPort Advanced Optics (AO) IOL (Bausch and Lomb) and a "parent" model, the conventional Soflex IOL, supported the manufacturer's claim that the AO lens does not induce aberrations, said Roberto Bellucci, MD, chief of the Ophthalmic Unit, Hospital of Verona, Italy.
FDA adds warning to tamsulosin labeling
January 1st 2006Chicago—This past October, the FDA issued a labeling change for the drug tamsulosin HCl (Flomax, Boehringer Ingelheim) warning of the possibility of intraoperative floppy iris syndrome (IFIS), stating "The patient's ophthalmologist should be prepared for possible modifications to their surgical technique."
Multifocal IOL provides high-quality vision for patients
January 1st 2006Chicago—The ReZoom multifocal IOL (AMO) provides excellent distance vision and useful near and intermediate vision to afford complete spectacle independence for 80% to 90% of patients with the lens implanted, said Michael C. Knorz, MD, at the Refractive Surgery Subspecialty Day Meeting sponsored by the International Society of Refractive Surgery of the American Academy of Ophthalmology.
Persistent traumatic mydriasis alleviated with cerclage pupilloplasty
December 15th 2005A patient complained of severe glare and light sensitivity associated with a persistent traumatic mydriasis of the right eye. After conservative treatment with topical miotics and a painted contact lens failed to decrease the mydriasis, a cerclage pupilloplasty was performed on the right eye resulting in a 4-mm round pupil. The patient experienced significant reduction of glare and photophobia.
Intravitreal anti-VEGF drugs are step forward in AMD management
December 15th 2005The promise of 2004, that new anti-vascular endothelial growth factor (VEGF) treatments for age-related macular degeneration (AMD) be developed, came to fruition in 2005, much to the excitement of ophthalmologists. These emerging treatments for AMD took center stage this year and resulted in numerous ideas about the effect of the pharmaceutical advancements and their impact on other retinal diseases.
Learn to maximize profitability at contact lens meeting
December 15th 2005Leading edge programming on contact lenses, solutions, and related eye-care issues is the focal point of the fourth annual Contact Lens and Eyecare Symposium (CLES), Jan. 11 to 15, 2006, at the Royal Pacific Resort at Universal Orlando, FL.
Winners of third annual Resident Writer's Award
December 15th 2005Chicago-Jason T. Halverson, MD, of the Albert Florens Storm Eye Institute at the Medical University of South Carolina, Charleston, was named the winner of the third annual Ophthalmology Times Resident Writer's Award Program. The program was sponsored by Advanced Medical Optics (AMO). In a presentation at the Ritz Carlton Hotel in October, Dr. Halverson was the first-place winner for a case study report of traumatic mydriasis that was managed by cerclage pupilloplasty to reduce pupillary aperture.
Resident Writer's Award Winner
December 15th 2005Jason T. Halverson, MD, a senior ophthalmology resident at Albert Florens Storm Eye Institute at the Medical University of South Carolina in Charleston, was named the winner of the third annual Ophthalmology Times Resident Writer's Award Program—presented during the American Academy of Ophthalmology annual meeting in Chicago. Dr. Halverson's winning submission is featured here. He was nominated by David T. Vroman, MD, associate professor of ophthalmology, Cornea, Cataract, and Refractive Surgery, Albert Florens Storm Eye Institute, Medical University of South Carolina.
Persistent traumatic mydriasis alleviated with cerclage pupilloplasty
December 15th 2005A patient complained of severe glare and light sensitivity associated with a persistent traumatic mydriasis of the right eye. After conservative treatment with topical miotics and a painted contact lens failed to decrease the mydriasis, a cerclage pupilloplasty was performed on the right eye resulting in a 4-mm round pupil. The patient experienced significant reduction of glare and photophobia.
Intravitreal anti-VEGF drugs are step forward in AMD management
December 15th 2005The promise of 2004, that new anti-vascular endothelial growth factor (VEGF) treatments for age-related macular degeneration (AMD) be developed, came to fruition in 2005, much to the excitement of ophthalmologists. These emerging treatments for AMD took center stage this year and resulted in numerous ideas about the effect of the pharmaceutical advancements and their impact on other retinal diseases.